Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Treatment of Proteinuria Due to Treatment Resistant or Treatment Intolerant Idiopathic Focal Segmental Glomerulosclerosis: A Prospective Study of Acthar (PODOCYTE)

NCT02633046 is registered in ClinicalTrials.gov with Mallinckrodt ARD LLC as lead sponsor.

NCT NCT02633046
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02633046 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Treatment of Proteinuria Due to Treatment Resistant or Treatment Intolerant Idiopathic Focal Segmental Glomerulosclerosis: A Prospective Study of Acthar (PODOCYTE)
Lead sponsor
Mallinckrodt ARD LLC
Phase
Phase 4
Overall status
Completed
Start date
October 10, 2016
Completion date
August 27, 2020
Enrollment
63 (actual)
Sites
47

Conditions

As the registry lists them; a condition with its own page is linked.

idiopathic focal segmental glomerulosclerosis